Role of T cell-nuclear factor κB in transplantation

Transplantation Reviews

Volumn 26, Issue 3, 2012, Pages 189-200

  Molinero, Luciana L ^a   Alegre, Maria Luisa ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 2; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR IMMUNITY; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; ORGAN TRANSPLANTATION; PROTEIN DOMAIN; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 84863089437     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.07.005     Document Type: Review

References (138)

1. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986, 47:921-928.
2. Silverman N., Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001, 15:2321-2342.
3. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
4. Oeckinghaus A., Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009, 1:a000034.
5. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
6. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
7. Gupta S.C., Sundaram C., Reuter S., Aggarwal B.B. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010, 1799:775-787.
8. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
9. Li Z., Nabel G.J. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol 1997, 17:6184-6190.
10. Hoffmann A., Levchenko A., Scott M.L., Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
11. Rao P., Hayden M.S., Long M., et al. IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 2010, 466:1115-1119.
12. Basak S., Kim H., Kearns J.D., et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007, 128:369-381.
13. Hatada E.N., Nieters A., Wulczyn F.G., et al. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc Natl Acad Sci U S A 1992, 89:2489-2493.
14. Franzoso G., Bours V., Azarenko V., et al. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J 1993, 12:3893-3901.
15. Bours V., Franzoso G., Azarenko V., et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993, 72:729-739.
16. Caamano J.H., Perez P., Lira S.A., Bravo R. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol 1996, 16:1342-1348.
17. Haruta H., Kato A., Todokoro K. Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs. J Biol Chem 2001, 276:12485-12488.
18. Okamoto K., Iwai Y., Oh-Hora M., et al. IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature 2010, 464:1381-1385.
19. Zhou H., Wertz I., O'Rourke K., et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004, 427:167-171. Epub 2003 Dec 2024.
20. Weil R., Schwamborn K., Alcover A., Bessia C., Di Bartolo V., Israel A. Induction of the NF-kappaB cascade by recruitment of the scaffold molecule NEMO to the T cell receptor. Immunity 2003, 18:13-26.
21. Vallabhapurapu S., Matsuzawa A., Zhang W., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008, 9:1364-1370.
22. Vaux D.L., Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005, 6:287-297.
23. Senftleben U., Cao Y., Xiao G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
24. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004, 279:26243-26250.
25. Zarnegar B., Yamazaki S., He J.Q., Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A 2008, 105:3503-3508.
26. Catz S.D., Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001, 20:7342-7351.
27. Wu M., Lee H., Bellas R.E., et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 1996, 15:4682-4690.
28. Grimm T., Schneider S., Naschberger E., et al. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005, 105:3263-3269.
29. Wang Z., Zhang B., Yang L., Ding J., Ding H.F. Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. JBiol Chem 2008, 283:10698-10706.
30. Wu M.X., Ao Z., Prasad K.V., Wu R., Schlossman S.F. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 1998, 281:998-1001.
31. Wegener E., Oeckinghaus A., Papadopoulou N., et al. Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. Mol Cell 2006, 23:13-23.
32. Hara H., Wada T., Bakal C., et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003, 18:763-775.
33. Blonska M., Pappu B.P., Matsumoto R., et al. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 2007, 26:55-66. Epub 2006 Dec 2028.
34. Medeiros R.B., Burbach B.J., Mueller K.L., et al. Regulation of NF-kappaB activation in T cells via association of the adapter proteins ADAP and CARMA1. Science 2007, 316:754-758.
35. 2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003, 197:1525-1535.
36. Sun Z., Arendt C.W., Ellmeier W., et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000, 404:402-407.
37. + T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol 2007, 178:2932-2939.
38. Verweij C.L., Geerts M., Aarden L.A. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-κB-like response element. J Biol Chem 1991, 266:14179-14182.
39. Ghosh P., Tan T.H., Rice N.R., Sica A., Young H.A. The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci U S A 1993, 90:1696-1700.
40. Rao S., Gerondakis S., Woltring D., Shannon M.F. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J Immunol 2003, 170:3724-3731.
41. Ishimaru N., Kishimoto H., Hayashi Y., Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat Immunol 2006, 7:763-772.
42. Boothby M.R., Mora A.L., Scherer D.C., Brockman J.A., Ballard D.W. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J Exp Med 1997, 185:1897-1907.
43. Stanic A.K., Bezbradica J.S., Park J.J., et al. NF-kappaB controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004, 172:2265-2273.
44. Schmidt-Supprian M., Courtois G., Tian J., et al. Mature T cells depend on signaling through the IKK complex. Immunity 2003, 19:377-389.
45. Egawa T., Albrecht B., Favier B., et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. Curr Biol 2003, 13:1252-1258.
46. Ruland J., Duncan G.S., Elia A., et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001, 104:33-42.
47. Ruefli-Brasse A.A., French D.M., Dixit V.M. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003, 302:1581-1584. Epub 2003 Oct 1523.
48. Jost P.J., Weiss S., Ferch U., et al. Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection. J Immunol 2007, 178:953-960.
49. Nagahama K., Nishimura E., Sakaguchi S. Induction of tolerance by adoptive transfer of Treg cells. Methods Mol Biol 2007, 380:431-442.
50. Gupta S., Manicassamy S., Vasu C., Kumar A., Shang W., Sun Z. Differential requirement of PKC-theta in the development and function of natural regulatory T cells. Mol Immunol 2008, 46:213-224. Epub 2008 Oct 2008.
51. + regulatory and natural killer-like T cells on signals leading to NF-{kappa}B activation. Proc Natl Acad Sci U S A 2004, 16:4566-4571.
52. + regulatory T cells. J Immunol 2009, 182:6736-6743.
53. Barnes M.J., Krebs P., Harris N., et al. Commitment to the regulatory T cell lineage requires CARMA1 in the thymus but not in the periphery. PLoS Biol 2009, 7:e51.
54. + CD4 regulatory T cells. J Exp Med 2009, 206:3001-3014.
55. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
56. Long M., Park S.G., Strickland I., Hayden M.S., Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009, 31:921-931.
57. + regulatory T cells. JImmunol 2006, 177:2186-2194.
58. Zanin-Zhorov A., Ding Y., Kumari S., et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010, 328:372-376.
59. Hanidziar D., Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant 2010, 15:411-415.
60. Corn R.A., Aronica M.A., Zhang F., et al. T cell-intrinsic requirement for NF-kappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response. J Immunol 2003, 171:1816-1824.
61. Balasubramani A., Shibata Y., Crawford G.E., Baldwin A.S., Hatton R.D., Weaver C.T. Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. Immunity 2010, 33:35-47.
62. Corn R.A., Hunter C., Liou H.C., Siebenlist U., Boothby M.R. Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation. J Immunol 2005, 175:2102-2110.
63. Franzoso G., Carlson L., Scharton-Kersten T., et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 1997, 6:479-490.
64. Marsland B.J., Nembrini C., Schmitz N., et al. Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A 2005, 102:14374-14379.
65. Tay S.S., Plain K.M., Bishop G.A. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009, 14:16-22.
66. Das J., Chen C.H., Yang L., Cohn L., Ray P., Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001, 2:45-50.
67. Kwon I.S., Lee K.H., Choi J.W., Ahn J.Y. PI(3,4,5)P3 regulates the interaction between Akt and B23 in the nucleus. BMB Rep 2010, 43:127-132.
68. Marsland B.J., Soos T.J., Spath G., Littman D.R., Kopf M. Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med 2004, 200:181-189.
69. Salek-Ardakani S., So T., Halteman B.S., Altman A., Croft M. Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase C theta. J Immunol 2004, 173:6440-6447.
70. Medoff B.D., Seed B., Jackobek R., et al. CARMA1 is critical for the development of allergic airway inflammation in a murine model of asthma. J Immunol 2006, 176:7272-7277.
71. Nakayama T., Kimura M.Y. Memory Th1/Th2 cell generation controlled by Schnurri-2. Adv Exp Med Biol 2010, 684:1-10.
72. Greve B., Weissert R., Hamdi N., et al. I kappa B kinase 2/beta deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis. J Immunol 2007, 179:179-185.
73. Marsland B.J., Nembrini C., Grun K., et al. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis. J Immunol 2007, 178:3466-3473.
74. Powolny-Budnicka I., Riemann M., Tanzer S., Schmid R.M., Hehlgans T., Weih F. RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent interleukin-17 production in gammadelta T cells. Immunity 2011, 34:364-374.
75. Visekruna A., Huber M., Hellhund A., et al. c-Rel is crucial for the induction of Foxp3(+) regulatory CD4(+) T cells but not T(H)17 cells. Eur J Immunol 2010, 40:671-676.
76. Jana S., Jailwala P., Haribhai D., et al. The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. Eur J Immunol 2009, 39:2571-2583.
77. Molinero L.L., Miller M.L., Evaristo C., Alegre M.L. High TCR stimuli prevent induced regulatory T cell differentiation in a NF-{kappa}B-dependent manner. J Immunol 2011.
78. Alegre M.L., Florquin S., Goldman M. Cellular mechanisms underlying acute graft rejection: time for reassessment. Curr Opin Immunol 2007, 19:563-568. Epub 2007 Aug 2027.
79. + T cells in their dependence of NF-kappa B/Rel signaling. Eur J Immunol 1999, 29:2968-2980.
80. Tian J., Pabst O., Romermann D., et al. Inactivation of T-cell receptor-mediated integrin activation prolongs allograft survival in ADAP-deficient mice. Transplantation 2007, 84:400-406.
81. Tian J., Rodriguez-Barbosa J.I., Pabst O., et al. ADAP deficiency combined with costimulation blockade synergistically protects intestinal allografts. Transpl Int 2010, 23:71-79.
82. Liou H.C., Jin Z., Tumang J., Andjelic S., Smith K.A., Liou M.L. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999, 11:361-371.
83. Berard M., Tough D.F. Qualitative differences between naive and memory T cells. Immunology 2002, 106:127-138.
84. Valujskikh A., Baldwin W.M., Fairchild R.L. Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant 2010, 10:1117-1125.
85. +CD44hi T cells bypasses Bcl10: an implication of differential NF-kappaB dependence of naive and memory T cells during T cell receptor-mediated responses. J Biol Chem 2008, 283:24392-24399.
86. + memory versus effector development. Science 2009, 323:502-505.
87. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003, 111:1887-1895.
88. Goldstein D.R. Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 2004, 16:538-544.
89. Kobayashi T., Walsh P.T., Walsh M.C., et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003, 19:353-363.
90. Ouaaz F., Arron J., Zheng Y., Choi Y., Beg A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002, 16:257-270.
91. Andreakos E., Williams R.O., Wales J., Foxwell B.M., Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci U S A 2006, 103:14459-14464.
92. + regulatory T cells. Autoimmunity 2006, 39:445-453.
93. Csizmadia V., Gao W., Hancock S.A., et al. Differential NF-kappaB and IkappaB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance. Transplantation 2001, 71:835-840.
94. Ma L., Xiang Z., Sherrill T.P., et al. Bioluminescence imaging visualizes activation of nuclear factor-kappaB in mouse cardiac transplantation. Transplantation 2008, 85:903-910.
95. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006, 6:2282-2291.
96. Arslan F., Keogh B., McGuirk P., Parker A.E. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm 2010, 704202:2010.
97. Chen L.W., Egan L., Li Z.W., Greten F.R., Kagnoff M.F., Karin M. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003, 9:575-581.
98. Onai Y., Suzuki J., Kakuta T., et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004, 63:51-59.
99. Cao C.C., Ding X.Q., Ou Z.L., et al. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 2004, 65:834-845.
100. Tsuchihashi S., Tamaki T., Tanaka M., et al. Pyrrolidine dithiocarbamate provides protection against hypothermic preservation and transplantation injury in the rat liver: the role of heme oxygenase-1. Surgery 2003, 133:556-567.
101. Luedde T., Assmus U., Wustefeld T., et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005, 115:849-859.
102. Tsung A., Sahai R., Tanaka H., et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005, 201:1135-1143.
103. Rusai K., Sollinger D., Baumann M., et al. Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr Nephrol 2010, 25:853-860.
104. Zanotti G., Casiraghi M., Abano J.B., et al. Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema. Am J Physiol Lung Cell Mol Physiol 2009, 297:L52-L63.
105. Ishiyama T., Dharmarajan S., Hayama M., Moriya H., Grapperhaus K., Patterson G.A. Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005, 130:194-201.
106. Ben Mkaddem S., Pedruzzi E., Werts C., et al. Heat shock protein gp96 and NAD(P)H oxidase 4 play key roles in Toll-like receptor 4-activated apoptosis during renal ischemia/reperfusion injury. Cell Death Differ 2010, 17:1474-1485.
107. Smiley S.T., Csizmadia V., Gao W., Turka L.A., Hancock W.W. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000, 70:415-419.
108. Finn P.W., He H., Ma C., et al. Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 2002, 72:1054-1062.
109. Yang H., Thomas D., Boffa D.J., et al. Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation 2002, 74:291-298.
110. Zhou P., Hwang K.W., Palucki D.A., et al. Impaired NF-kB activation in T cells permits tolerance to primary heart allografts and to secondary donor skin grafts. Am J Transplant 2003, 3:139-147.
111. Zhou P., Balin S.J., Mashayekhi M., Hwang K.W., Palucki D.A., Alegre M.L. Transplantation tolerance in NF-kappaB-impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. J Immunol 2005, 174:3447-3453.
112. Molinero L.L., Wang Y., Zhou P., Yagita H., Alegre M.L. Fas mediates cardiac allograft acceptance in mice with impaired T cell-intrinsinc NF-kB signaling. Transpl Int 2009, Accepted with minor revisions.
113. Molinero L., Zhou P., Wang Y., et al. Epidermal Langerhans cells play a major role in skin allograft rejection in mice with NF-kB-impaired T cells. Am J Transplant 2008, 8:21-31.
114. Manicassamy S., Yin D., Zhang Z., Molinero L.L., Alegre M.L., Sun Z. A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection. J Immunol 2008, 181:513-520.
115. Chin A.I., Dempsey P.W., Bruhn K., Miller J.F., Xu Y., Cheng G. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 2002, 416:190-194.
116. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191-202.
117. Ruefli-Brasse A.A., Lee W.P., Hurst S., Dixit V.M. Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappaB activation. J Biol Chem 2004, 279:1570-1574.
118. Fairhead T., Lian D., McCully M.L., Garcia B., Zhong R., Madrenas J. RIP2 is required for NOD signaling but not for Th1 cell differentiation and cellular allograft rejection. Am J Transplant 2008, 8:1143-1150.
119. Sanchez-Valdepenas C., Casanova L., Colmenero I., et al. Nuclear factor-kappaB inducing kinase is required for graft-versus-host disease. Haematologica 2010, 95:2111-2118.
120. Bonham C.A., Peng L., Liang X., et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002, 169:3382-3391.
121. + anaplastic large cell lymphoma. Leukemia 2007, 21:838-842.
122. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
123. + T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009, 94:975-983.
124. Trivedi H.L., Terasaki P.I., Feroz A., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87:1555-1561.
125. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6:1111-1131.
126. Wissink S., van Heerde E.C., vand der Burg B., van der Saag P.T. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol 1998, 12:355-363.
127. Nadler S.G., Eversole A.C., Tepper M.A., Cleaveland J.S. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995, 17:700-703.
128. Kerr P.G., Atkins R.C. The effects of deoxyspergualin on human lymphocyte proliferation in vitro. Transplant Proc 1989, 21:3765-3766.
129. Ramos E.L., Nadler S.G., Grasela D.M., Kelley S.L. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996, 28:873-875.
130. Jiang H., Takahara S., Kyo M., et al. In vivo and in vitro mechanisms of cardiac allograft acceptance in the rat after short treatment with 15-deoxyspergualin. Transplant Int 1992, 5:139-144.
131. Kaufman D.B., Field M.J., Gruber S.A., et al. Extended functional survival of murine islet allografts with 15- deoxyspergualin. TransplantProc 1992, 24:1045-1047.
132. Jiang H., Takahara S., Kyo M., Kokado Y., Ishibashi M., Sonoda T. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. Eur Surg Res 1991, 23:201-205.
133. Raisanen-Sokolowski A., Yilmaz S., Tufveson G., Hayry P. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin. Transplantation 1994, 57:1772-1777.
134. Min W.P., Zhou D., Ichim T.E., et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003, 170:1304-1312.
135. Heslan J.M., Beriou G., Le Luduec J.B., et al. Accumulation of T cells with potent regulatory properties and restricted Vbeta7-TCR rearrangements in tolerated allografts. Transplantation 2005, 80:1476-1484.
136. Le Texier L., Thebault P., Lavault A., et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011, 11:429-438.
137. Yang H., Chen G., Kanai N., et al. Monotherapy with LF 15-0195, an analogue of 15-deoxyspergualin, significantly prolongs renal allograft survival in monkeys. Transplantation 2003, 75:1166-1171.
138. Kawagishi N., Takeda I., Miyagi S., et al. Long-term outcome of ABO-incompatible living-donor liver transplantation: a single-center experience. J Hepatobiliary Pancreat Surg 2009, 16:468-472.